Overview

Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)

Status:
Not yet recruiting

Trial end date:
2025-12-30

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus lenvatinib as first-line treatment in patients with advanced ICC.

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Treatments:

Lenvatinib